Atazanavir and artesunate were identified as candidate small molecules for binding with RPL35/uL29 and possibly trigger increased production of full-length Lamb3 protein from LAMB3PTC mRNA for targeted systemic therapy in treating JEB patients [175]. Here, RPL35 is linked to junctional epidermolysis bullosa.